Molecular and immune targets in cutaneous squamous cell carcinoma

Mol Carcinog. 2023 Jan;62(1):38-51. doi: 10.1002/mc.23451. Epub 2022 Aug 24.


Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer and often confers a good prognosis. Though surgery is the gold standard of treatment, unresectable or metastatic disease can necessitate systemic therapy. Of systemic agents, there is increasing interest in the use of immunotherapies and targeted therapy. Further study into the driver mutations in cSCC has identified opportunities for targeted therapy. In this review, we discuss both current and investigational immune and molecular targets of therapy for cSCC.

Keywords: checkpoint inhibitors; cutaneous squamous cell carcinoma; immunotherapy; targeted therapies.

Publication types

  • Review

MeSH terms

  • Carcinoma, Squamous Cell* / genetics
  • Carcinoma, Squamous Cell* / therapy
  • Humans
  • Immunotherapy
  • Skin Neoplasms* / genetics
  • Skin Neoplasms* / therapy